As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.
25 Analysts have issued a IDEAYA Biosciences Inc forecast:
25 Analysts have issued a IDEAYA Biosciences Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 215 215 |
5,380%
5,380%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -207 -207 |
7%
7%
|
|
| EBIT (Operating Income) EBIT | -209 -209 |
7%
7%
|
|
| Net Profit | -160 -160 |
10%
10%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Yujiro Hata |
| Employees | 131 |
| Founded | 2015 |
| Website | www.ideayabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


